Product Information
DEXILANT DR 30 MG CAPSULE is a brand product labeled by Takeda Pharmaceuticals America, Inc., priced at $9.8526 per EA under NDC 64764017130. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Jan 30, 2009. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the dexlansoprazole market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
30 mg/1
Manufacturer
Takeda Pharmaceuticals America, Inc.NDC
64764017130
Classification
Brand
Dosage Form
CAPSULE, DELAYED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DEXLANSOPRAZOLEApproval Type
New Drug (NDA)
FDA Application
NDA022287FDA Approved
1/30/2009
TE Code
AB
On Market Since
4/12/2010
Pharmacological Classes
Price Statistics
The NADAC for DEXILANT DR 30 MG CAPSULE has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 83.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $9.8526 per EA |
|---|---|
| All-time high | $9.8767 (Jun 14, 2023) |
| All-time low | $5.3833 (Nov 28, 2013) |
| 52-week high | $9.8529 |
| 52-week low | $9.8341 |
| Median price | $9.2959 |
| Average price | $8.7737 |
| Largest weekly change | +9.9% (Jun 10, 2015) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 62% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Takeda Pharmaceuticals America, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
dexlansoprazole market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Proton Pump Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DEXILANT DR 30 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for DEXILANT DR 30 MG CAPSULE, manufactured by Takeda Pharmaceuticals America, Inc., is $9.8526 per EA (NDC 64764017130), effective Sep 30, 2026.
How has the price of DEXILANT DR 30 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for DEXILANT DR 30 MG CAPSULE has risen 83.0%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for DEXILANT DR 30 MG CAPSULE?
Since Nov 28, 2013, the NADAC for DEXILANT DR 30 MG CAPSULE has ranged from a low of $5.3833 (Nov 28, 2013) to a high of $9.8767 (Jun 14, 2023), with a median of $9.2959 per EA.
Are there cheaper alternatives to DEXILANT DR 30 MG CAPSULE?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, DEXLANSOPRAZOLE DR 30 MG CAP, is $3.7727 per EA — about 62% below DEXILANT DR 30 MG CAPSULE.
Who manufactures DEXILANT DR 30 MG CAPSULE?
DEXILANT DR 30 MG CAPSULE (NDC 64764017130) is labeled by Takeda Pharmaceuticals America, Inc., and CMS classifies it as a brand product.